Joint Bookrunner on Perspective Therapeutics Registered Direct Offering

Oppenheimer & Co. Inc. June 03, 2024
Oppenheimer & Co. Inc. acted as Joint Bookrunner on Perspective Therapeutics’ $80MM Registered Direct Offering

Perspective Therapeutics, Inc. (“Perspective”) (NYSEAM: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, announced the pricing of an underwritten offering of 51,515,880 shares of its common stock at an offering price of $1.51 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 1,464,252 shares of its common stock at a price of $1.509 per pre-funded warrant. The aggregate gross proceeds from this offering are expected to be approximately $80 million, before deducting underwriting discounts and other offering expenses.

Perspective intends to use the net proceeds that it will receive from the offering for: (i) the continued clinical development of VMT-α-NET, VMT-01/02 and PSV359; (ii) the continued development of PSV40X and additional preclinical product candidates as well as broader development platform; and (iii) the build out, operation and expansion of manufacturing facilities, as well as for working capital and other general corporate purposes. A portion of the net proceeds may also be used to acquire, license or invest in complementary products, technologies, intellectual property or businesses, although Perspective has no present commitments or agreements to do so.

Michael Margolis
Name:

Michael A. Margolis, R.Ph.

Title:

Senior Managing Director, Co-Head of Healthcare, Head of Healthcare Life Sciences

Name:

DISCLOSURES

This notice is provided for informational purposes only, and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.

This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.

2024 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 6653977.1